Stocks Health care TYRA
NASDAQ · Health careTyra Biosciences, Inc. (TYRA)
It posted a net loss of $148.6M. In fiscal 2025 capital spending exceeded operating cash flow by $95.3M. At June 30, 2026 it held $73.8M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 4, 2026.
Key facts about Tyra Biosciences, Inc.
- Net worth
- Tyra Biosciences, Inc. has a market value (market cap) of $1.3B at the latest share price, and shareholders' equity of $353.7M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Cash flow
- In fiscal 2025 operations used $95.1M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 4, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Tyra Biosciences, Inc.'s next report was expected around November 4, 2026 and is not on file with the SEC yet.
What Tyra Biosciences, Inc. does
Tyra Biosciences, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker TYRA.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$119.9M | -$2.01 | -$95.3M |
| 2024 | n/a | -$86.5M | -$1.51 | -$70.4M |
| 2023 | n/a | -$69.1M | -$1.62 | -$50.9M |
| 2022 | n/a | -$55.3M | -$1.32 | -$50.8M |
| 2021 | n/a | -$26.3M | -$1.91 | -$24.4M |
| 2021 | n/a | -$9.3M | -$6.05 | -$8.1M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Tyra Biosciences, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- October 27, 2026Passive stake changed SCHEDULE 13G/A
- September 21, 2026Passive stake (5% or more) SCHEDULE 13G
- September 17, 2026Activist stake changed SCHEDULE 13D/A
- September 17, 2026Passive stake (5% or more) SCHEDULE 13G
- September 15, 2026Other event 8-K
- September 14, 2026
- September 9, 2026Other event 8-K
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 4, 2026
Insider trades
What the people running Tyra Biosciences, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders bought $20K worth of shares on the open market in the last 90 days and sold none.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 15, 2026 | Fuhrman AlanChief Financial Officer | Received as pay | 951 | $8.7K |
| September 15, 2026 | Rueb YuliyaVice President, Finance (PAO) | Received as pay | 2,925 | $26.7K |
| September 15, 2026 | Harris ToddPresident and CEO, Director | Received as pay | 864 | $7.9K |
| September 9, 2026 | Verjee RehanDirector | Bought | 972 | $20K |
| May 5, 2026 | Rueb YuliyaVice President, Finance (PAO) | Received as pay | 8,333 | - |
| May 5, 2026 | Ashar BhaveshChief Operating Officer | Received as pay | 15,013 | - |
| May 5, 2026 | Harris ToddPresident and CEO, Director | Received as pay | 79,000 | - |
| May 5, 2026 | Fuhrman AlanChief Financial Officer | Received as pay | 20,000 | - |
Who owns TYRA
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| RA Capital Management, L.P.13D, may seek influence with 3 related filers | 19.9% | September 17, 2026 |
| Fmr LLC13G, passive with 1 related filers | 14.4% | April 7, 2026 |
| Boxer Capital, LLC13D, may seek influence with 5 related filers | 12.3% | February 8, 2024 |
| Janus Henderson Group PLC13G, passive | 7.2% | May 15, 2026 |
| Dapice Joshua J.13G, passive with 27 related filers | 6.6% | May 12, 2026 |
| Bvf Partners L P13G, passive with 9 related filers | 6.1% | September 21, 2026 |
| Nextech VI Oncology SCSp13G, passive with 4 related filers | 6% | August 14, 2026 |
| Paradigm BioCapital Advisors LP13G, passive with 3 related filers | 5.8% | September 17, 2026 |
| TCG Crossover GP I, LLC13G, passive with 2 related filers | 5.7% | March 6, 2025 |
| Aaron I. Davis13D, may seek influence with 2 related filers | 5% | December 6, 2024 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 170 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| RA Capital Management, L.P. | 12,198,625 | 0 |
| Fmr LLC | 8,920,513 | +1,172,865 |
| Jupiter Topco LLC | 4,352,448 | new |
| Alta Partners Management Company, L.P. | 3,823,425 | 0 |
| Nextech Invest Ltd. | 3,553,585 | -502,276 |
| TCG Crossover Management, LLC | 3,248,980 | 0 |
| BlackRock, Inc. | 3,031,972 | +814,043 |
| State Street Corp | 2,140,368 | +924,290 |
| Commodore Capital LP | 1,875,000 | -600,000 |
| Paradigm Biocapital Advisors LP | 1,828,607 | -226,384 |
| Vanguard Capital Management LLC | 1,508,447 | +382,477 |
| Bvf Inc | 1,476,196 | -500,000 |
| 5AM Venture Management, LLC | 1,029,298 | 0 |
| Deerfield Management Company, L.P. | 1,017,000 | +468,000 |
| Hood River Capital Management LLC | 1,016,775 | new |
| Geode Capital Management, LLC | 970,734 | +312,252 |
| Caligan Partners LP | 806,986 | -469,982 |
| Canaan Partners XI LLC | 750,000 | 0 |
| Siren, L.L.C. | 725,000 | new |
| Sio Capital Management, LLC | 695,315 | +89,876 |
Insiders
9 insiders reported holding 5,526,490 shares in total, about $123.2M at the last price.
| Holder | Shares |
|---|---|
| More Robert JDirector | 3,823,4253,823,425 held indirectly |
| Harris ToddPresident and CEO, Director | 1,438,495 |
| Bensen DanielChief Discovery Officer | 146,981 |
| Fuhrman AlanChief Financial Officer | 37,115 |
| Kaplan GillaDirector | 28,231 |
| Warner Douglas JChief Medical Officer | 25,000 |
| Ashar BhaveshChief Operating Officer | 15,013 |
| Rueb YuliyaVice President, Finance (PAO) | 11,258 |
| Verjee RehanDirector | 972 |
Questions about TYRA
What does Tyra Biosciences, Inc. do?
Tyra Biosciences, Inc. is a company in the Health care sector, listed on NASDAQ as TYRA. Its shares trade on NASDAQ under the ticker TYRA.
What is Tyra Biosciences, Inc.'s net worth?
Tyra Biosciences, Inc. has a market value (market cap) of $1.3B at the latest share price, and shareholders' equity of $353.7M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Tyra Biosciences, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $148.6M.
When did Tyra Biosciences, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 4, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the passive stake changed from October 27, 2026.
When is Tyra Biosciences, Inc.'s next earnings report?
Tyra Biosciences, Inc.'s next report was expected around November 4, 2026 and is not on file with the SEC yet.
Similar companies
Compare TYRA with
Follow TYRA
Get an email when Tyra Biosciences, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Tyra Biosciences, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.